EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Validation of Aspartylglucosaminidase Activity Assay for Human Serum Samples: Establishment of a Biomarker for Diagnostics and Clinical Studies

Antje Banning, Minna Laine, Ritva Tikkanen iD

International Journal of Molecular Sciences · 16.03.2023 · 24 (6) · 5722

DOI: 10.3390/ijms24065722 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.03.2023. Verfasst von Antje Banning und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry, Medical Faculty, University of Giessen, Friedrichstrasse 24, DE-35390 Giessen, Germany. Hauptthemen laut MEDLINE: Aspartylglucosylaminase, Aspartylglucosaminuria, Lysosomal Storage Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jane and Aatos Erkko Foundation, Suomen AGU r.y..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel treatment strategies are emerging for rare, genetic diseases, resulting in clinical trials that require adequate biomarkers for the assessment of the treatment effect. For enzyme defects, biomarkers that can be assessed from patient serum, such as enzyme activity, are highly useful, but the activity assays need to be properly validated to ensure a precise, quantitative measurement. Aspartylglucosaminuria (AGU) is a lysosomal storage disorder caused by the deficiency of the lysosomal hydrolase aspartylglucosaminidase (AGA). We have here established and validated a fluorometric AGA activity assay for human serum samples from healthy donors and AGU patients. We show that the validated AGA activity assay is suitable for the assessment of AGA activity in the serum of healthy donors and AGU patients, and it can be used for diagnostics of AGU and, potentially, for following a treatment effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspartylglucosylaminaseAspartylglucosaminuriaLysosomal Storage DiseasesHumansLysosomes

Stichwörter der Autor:innen

aspartylglucosaminuriabiomarkersenzymeslysosomal storage disordersprotein glycosylation

Substanzen

Aspartylglucosylaminase

Autor:innen und Institutionen

  • Institute of Biochemistry, Medical Faculty, University of Giessen, Friedrichstrasse 24, DE-35390 Giessen, Germany.
  • Department of Child Neurology, Helsinki University Hospital and Helsinki University, P.O. Box 900, FI-01400 Vantaa, Finland.

ORCID-Profile: Ritva Tikkanen

Förderung

  • Jane and Aatos Erkko Foundation
  • Suomen AGU r.y.

Zitieren

APA

Banning, A., Laine, M., & Tikkanen, R. (2023). Validation of Aspartylglucosaminidase Activity Assay for Human Serum Samples: Establishment of a Biomarker for Diagnostics and Clinical Studies. International Journal of Molecular Sciences, 24(6), 5722. https://doi.org/10.3390/ijms24065722

Vancouver

Banning A, Laine M, Tikkanen R. Validation of Aspartylglucosaminidase Activity Assay for Human Serum Samples: Establishment of a Biomarker for Diagnostics and Clinical Studies. International Journal of Molecular Sciences. 2023;24(6):5722. doi:10.3390/ijms24065722

BibTeX
@article{Banning2023,
  author = {Banning, Antje and Laine, Minna and Tikkanen, Ritva},
  title = {Validation of Aspartylglucosaminidase Activity Assay for Human Serum Samples: Establishment of a Biomarker for Diagnostics and Clinical Studies},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {6},
  pages = {5722},
  doi = {10.3390/ijms24065722}
}
Kostenlos starten →